Patents by Inventor Yoel Kloog
Yoel Kloog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160082161Abstract: Composite structures composed of a device as a core structure, being a medical device or article, and a porous polymeric coat and designed capable of encapsulating bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures.Type: ApplicationFiled: December 3, 2015Publication date: March 24, 2016Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Meital ZILBERMAN, Yoel KLOOG, Amir KRAITZER, Jonathan ELSNER
-
Publication number: 20150238466Abstract: The invention relates to compounds for reducing or inhibiting a biological function mediated by LIMK1 or LIMK2, wherein the compounds are selected to bind the ATP-binding site and/or the substrate-binding site of LIMK.Type: ApplicationFiled: June 27, 2013Publication date: August 27, 2015Inventors: Yoel Kloog, Haim Wolfson, Shmuel Carmeli, Efrat Farkash, Roni Rak, Galit Elad-Sfadia, Roni Haklai
-
Publication number: 20140088123Abstract: Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoel Kloog, Adi Zundelevich, Roni Haklai
-
Publication number: 20130123365Abstract: Disclosed are methods of treating a mammalian subject afflicted with a non-autoimmune inflammatory condition, comprising administering to the subject a pharmaceutical composition comprising an effective amount of S-farnesylthiosalicylic acid (FTS) or a structural analog thereof, and compositions useful in the practice of the methods.Type: ApplicationFiled: July 7, 2011Publication date: May 16, 2013Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoseph A. Mekori, Adam Mor, Yoel Kloog
-
Publication number: 20130116326Abstract: Disclosed are methods of treating a mammalian subject afflicted with a delayed cutaneous hypersensitivity condition, comprising administering to the subject a pharmaceutical composition comprising an effective amount of S-farnesylthiosalicylic acid (FTS) or a structural analog thereof, and compositions for use in the methods.Type: ApplicationFiled: July 7, 2011Publication date: May 9, 2013Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoseph A. Mekori, Adam Mor, Yoel Kloog
-
Publication number: 20130035390Abstract: Disclosed are methods for treating multiple sclerosis patients that entail co-administration of effective amounts of a Ras antagonist which is farnesylthiosalicylic acid or an analog thereof, and a second active agent selected from glatiramer acetate, laquinimod and combinations thereof. Therapeutic compositions and methods of making them are also disclosed.Type: ApplicationFiled: January 13, 2011Publication date: February 7, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Elizabeta Aizman, Joab Chapman
-
Patent number: 8338481Abstract: Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed.Type: GrantFiled: January 20, 2010Date of Patent: December 25, 2012Assignees: Ramot at Tel-Aviv University Ltd., Kadmon Corporation, LLCInventors: Yoel Kloog, Liat Goldberg, Victor J. Bauer
-
Publication number: 20120294957Abstract: Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.Type: ApplicationFiled: July 27, 2012Publication date: November 22, 2012Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoel Kloog, Adi Zundelevich, Roni Haklai
-
Patent number: 8278349Abstract: Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed.Type: GrantFiled: November 6, 2006Date of Patent: October 2, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Liat Goldberg, Michael Brownstein
-
Patent number: 8268889Abstract: Disclosed are methods of treating ovarian cancer by administering an effective amount of FTS (farnesylthiosalicylic acid), or various analogs thereof, or a pharmaceutically acceptable salt, optionally with, a platinum-based chemotherapy drug to a human diagnosed with ovarian cancer.Type: GrantFiled: February 1, 2007Date of Patent: September 18, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Gilad Ben-Baruch
-
Patent number: 8232253Abstract: Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.Type: GrantFiled: December 17, 2007Date of Patent: July 31, 2012Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Adi Zundelevich, Roni Haklai
-
Publication number: 20110130369Abstract: Disclosed are methods for reducing the extent of myocardial ischemia/reperfusion injury, comprising administering to a human prior to reperfusion of the ischemic myocardium or pre-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof. Methods of treating ischemia/reperfusion injury, comprising administering to a human after reperfusion of the ischemic myocardium or post-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof are also disclosed.Type: ApplicationFiled: June 4, 2009Publication date: June 2, 2011Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoel Kloog, Jakob George, Gad Keren, Rakefet Pando
-
Publication number: 20110091515Abstract: Composite structures composed of a device as a core structure, being a medical device or article, and a porous polymeric coat and designed capable of encapsulating bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures.Type: ApplicationFiled: June 11, 2009Publication date: April 21, 2011Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Meital Zilberman, Yoel Kloog, Amir Kraitzer, Jonathan Elsner
-
Publication number: 20110046223Abstract: Disclosed are methods of treating neurofibromatosis by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with colchicine. Also disclosed are pharmaceutical compositions comprising FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof; colchicine; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 14, 2007Publication date: February 24, 2011Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoel Kloog, Shiran Kringel, Eitan Friedman, Reuven Stein
-
Publication number: 20100189781Abstract: Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed.Type: ApplicationFiled: January 20, 2010Publication date: July 29, 2010Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., CONCORDIA PHARMACEUTICALS, INC.Inventors: Yoel Kloog, Liat Goldberg, Victor J. Bauer
-
Publication number: 20100144873Abstract: Disclosed are methods of treating myocarditis by—administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 17, 2009Publication date: June 10, 2010Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoel Kloog, Jakob George, Gad Keren, Rakefet Pando
-
Publication number: 20100136138Abstract: Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed.Type: ApplicationFiled: December 17, 2007Publication date: June 3, 2010Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Yoel Kloog, Adi Zundelevich, Roni Haklai
-
Publication number: 20090298843Abstract: Disclosed are methods of treating a hematological malignancy by administering to a human in need thereof effective amounts of FTS (Farnesylthiosalicylic Acid), or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally in combination with a Bcr-Abl tyrosine kinase inhibitor. Also disclosed are pharmaceutical compositions comprising FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, a Bcr-Abl tyrosine kinase inhibitor, preferably Imatinib and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 10, 2007Publication date: December 3, 2009Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Yoel Kloog, Itay Nakdimon
-
Publication number: 20090286870Abstract: Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed.Type: ApplicationFiled: November 6, 2006Publication date: November 19, 2009Applicant: RAMOT AT TEL AVIV UNIVERSITY, LTD.Inventors: Yoel Kloog, Liat Goldberg, Michael Brownstein
-
Publication number: 20090226539Abstract: Disclosed are methods of treating ovarian cancer by administering an effective amount of FTS (farnesylthiosalicylic acid), or various analogs thereof, or a pharmaceutically acceptable salt, optionally with, a platinum-based chemotherapy drug to a human diagnosed with ovarian cancer.Type: ApplicationFiled: February 1, 2007Publication date: September 10, 2009Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Yoel Kloog, Gilad Ben-Baruch